Overview

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Status:
Terminated

Trial end date:
2018-03-26

Target enrollment:

Participant gender:

Summary

This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Collaborators:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.

Treatments:

Calcium, Dietary
Denosumab
Ergocalciferols
Vitamin D
Vitamins